加载中
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), as well as for the treatment of other exudative and neovascular retinal diseases.
常规交易时段
US$2.3795
+US$0.0195 · +0.83%
盘中时间采用ET。市场数据可能有所延迟。
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), as well as for the treatment of other exudative and neovascular retinal diseases.
日内区间
当前US$2.3795
52周区间
当前US$2.3795
盘中时间采用ET。市场数据可能有所延迟。
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), as well as for the treatment of other exudative and neovascular retinal diseases.
日内区间
当前US$2.3795
52周区间
当前US$2.3795
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 销货成本 | 1.3万 USD | — | — | — | 111.7万 USD |
| 毛利 | −1.3万 USD | — | — | — | −111.7万 USD |
| 研究与开发 | 3075.3万 USD | 1234万 USD | 1170.7万 USD | 1176.3万 USD | 1.2亿 USD |
| 销售、一般及管理费用 | 1538.6万 USD | 4291.6万 USD | 175.7万 USD | 224.3万 USD | 4908.3万 USD |
| 营业费用 | 4613.9万 USD | 5525.6万 USD | 1346.4万 USD | 1400.6万 USD | 1.69亿 USD |
| 利息收入 | — | 548.6万 USD | — | — | 131.5万 USD |
| 利息支出 | 144.3万 USD | — | 68.7万 USD | 23.5万 USD | — |
| 折旧和摊销 | 1.3万 USD | — | — | — | 111.7万 USD |
| 营业利润 | −4615.2万 USD | −5525.6万 USD | −1346.4万 USD | −1400.6万 USD | −1.7亿 USD |
| 净利润 | −4343.8万 USD | −5876.9万 USD | −1469.9万 USD | −1548.5万 USD | −1.72亿 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$15.50
上涨空间 551.40%| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2025年1月16日 | 1:23 | — | — |
已生效 2025年1月16日
1:23
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI103.16万0.00%2.3万亿 USD0.03%US$381.91-0.01%
Vanguard Extended Market ETFVXF55.5万0.00%954亿 USD0.05%US$234.54-0.20%
iShares Micro-Cap ETFIWC6.8万0.01%13.17亿 USD0.60%US$182.56-0.24%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM5万0.05%1.17亿 USD0.73%US$15.86-0.50%
U.S. Core Equity 1 Portfolio ETF Class SharesDCOR82400.00%455.91亿 USD0.17%US$84.44+0.05%
U.S. Vector Equity Portfolio ETF Class SharesDXUV68750.00%61.81亿 USD0.26%US$68.455+0.26%
Dimensional - US Core Equity 2 ETFDFAC65350.00%885.96亿 USD0.21%US$45.385+0.12%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMU.S. Core Equity 1 Portfolio ETF Class SharesDCORU.S. Vector Equity Portfolio ETF Class SharesDXUVDimensional - US Core Equity 2 ETFDFACAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
